V(D)J recombination and DNA repair: Lessons from human immune deficiencies and other animal models

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 6, 2002, Pages 473-479

  De Villartay, Jean Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Artemis; DNA repair; Genomic caretaker lymphomas; V(D)J recombination

Indexed keywords

BETA LACTAMASE; GENE PRODUCT; METALLOPROTEIN; MUTANT PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAG1 PROTEIN; RAG2 PROTEIN;

ANIMAL MODEL; B LYMPHOCYTE; CANCER; CANCER SUSCEPTIBILITY; CHROMOSOME TRANSLOCATION; COMBINED IMMUNODEFICIENCY; DNA REPAIR; DNA TRANSPOSITION; ENZYME DEFICIENCY; GENE INACTIVATION; GENE MUTATION; GENETIC RECOMBINATION; GENETIC VARIABILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENETICS; KNOCKOUT MOUSE; NONHUMAN; OMENN SYNDROME; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; T LYMPHOCYTE;

ANIMALS; BETA-LACTAMASES; DNA REPAIR; GENOMICS; HUMANS; LINKAGE (GENETICS); LYMPHOMA; MICE; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; SEVERE COMBINED IMMUNODEFICIENCY; VDJ RECOMBINASES;

EID: 0036959045     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200212000-00001     Document Type: Review

References (84)

1. Gellert M. V(D)J recombination: rag proteins, repair factors, and regulation. Annu Rev Biochem 2002; 71:101-132. See annotation to Ref. [3•].
2. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002; 109:S45-S55. See annotation to Ref. [3•].
3. Brandt VL, Roth DB. A recombinase diversified: new functions of the RAG proteins. Curr Opin Immunol 2002; 14:224-229. These three papers (Refs [1•-3•]) constitute excellent reviews that cover most of the aspects of V(D)J recombination.
4. Haber JE. Partners and pathways repairing a double-strand break. Trends Genet 2000; 16:259-264.
5. Moshous D, Callebaut I, de Chasseval R, et al. ARTEMIS, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001; 105:177-186. Molecular analysis of RS-SCID patients led to the identification and cloning of a new factor of the V(D)J recombination/DNA repair. See Ref. [50••] for a demonstration of the role of Artemis in hairpin opening in vitro.
6. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1 deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869-877.
7. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68:855-867.
8. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. The Lancet 2001; 357:1863-1869.
9. Villa A, Sobacchi C, Vezzoni P. Recombination activating gene and its defects. Curr Opin Allergy Clin Immunol 2001; 1:491-495. Excellent review on T-B-SCID caused by mutations in either Rag1 or Rag2 genes and their relevance to the physiology of V(D)J recombination.
10. Callebaut I, Mornon JP. The V(D)J recombination activating protein RAG2 consists of a six-bladed propeller and a PHD fingerlike domain, as revealed by sequence analysis. Cell Mol Life Sci 1998; 54:880-891.
11. Corneo B, Moshous D, Callebaut I, et al. 3D clustering of human RAG2 gene mutations in severe combined immune deficiency (SCID). J Biol Chem 2000; 275:12672-12675.
12. Aasland R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 1995; 20:56-59.
13. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97:81-88.
14. Steen SB, Han J, Mundy C, et al. Roles of the 'dispensable' portions of RAG-1 and RAG-2 in V(D)J recombination, Mol Cell Biol 1999; 19:3010-3017.
15. Bogue MA, Jhappan C, Roth DB. Analysis of variable (diversity) joining recombination in DNA-dependent protein kinase (DNA-PK)-deficient mice reveals DNA-PK-independent pathways for both signal and coding joint formation. Proc Natl Acad Sci U S A 1998; 95:15559-15564.
16. Bogue MA, Wang CY, Zhu CM, Roth DB. V(D)J recombination in Ku86-deficient mice: distinct effects on coding, signal, and hybrid joint formation. Immunity 1997; 7:37-47.
17. Sekiguchi JA, Whitlow S, Alt FW. Increased accumulation of hybrid V(D)J joins in cells expressing truncated versus full-length RAGs. Mol Cell 2001; 8:1383-1390.
18. Fugmann SD, Villey IJ, Ptaszek LM, Schatz DG. Identification of two catalytic residues in RAG1 that define a single active site within the RAG1/RAG2 protein complex. Mol Cell 2000; 5:97-107.
19. Kim DR, Dai Y, Mundy CL, et al. Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev 1999; 13:3070-3080.
20. Landree MA, Wibbenmeyer JA, Roth DB. Mutational analysis of RAG1 and RAG2 identifies three catalytic amino acids in RAG1 critical for both cleavage steps of V(D)J recombination. Genes Dev 1999; 13:3059-3069.
21. Li W, Chang FC, Desiderio S. Rag-1 mutations associated with B-cell-negative scid dissociate the nicking and transesterification steps of V(D)J recombination. Mol Cell Biol 2001; 21:3935-3946. See annotation to Ref. [26°].
22. Fugmann SD, Schatz DG. Identification of basic residues in RAG2 critical for DNA binding by the RAG1-RAG2 complex. Mol Cell 2001; 8:899-910. See annotation to Ref. [26•].
23. Huye LE, Purugganan MM, Jiang MM, Roth DB. Mutational analysis of all conserved basic amino acids in RAG-1 reveals catalytic, step arrest, and joining-deficient mutants in the V(D)J recombinase. Mol Cell Biol 2002; 22:3460-3473. See annotation to Ref. [26•].
24. Kale SB, Landree MA, Roth DB. Conditional RAG-1 mutants block the hairpin formation step of V(D)J recombination. Mol Cell Biol 2001; 21:459-466. See annotation to Ref. [26•].
25. Qiu JX, Kale SB, Yarnell Schultz H, Roth DB. Separation-of-function mutants reveal critical roles for RAG2 in both the cleavage and joining steps of V(D)J recombination. Mol Cell 2001; 7:77-87. See annotation to Ref. [26•].
26. Yarnell Schultz H, Landree MA, Qiu JX, et al. Joining-deficient RAG1 mutants block V(D)J recombination in vivo and hairpin opening in vitro. Mol Cell 2001; 7:65-75. Comprehensive series of six papers (Refs [21•-26•]) using extensive in-vitro mutagenesis approaches to define critical residues in Rag1/2 involved in the different phases of the recombination process.
27. Landree MA, Kale SB, Roth DB. Functional organization of single and paired v(d)j cleavage complexes. Mol Cell Biol 2001; 21:4256-4264. See annotation to Ref. [29•].
28. Mundy CL, Patenge N, Matthews AG, Oettinger MA. Assembly of the RAG1/ RAG2 synaptic complex. Mol Cell Biol 2002; 22:69-77. See annotation to Ref. [29•].
29. Jones JM, Gellert M. Intermediates in V(D)J recombination: a stable RAG1/2 complex sequesters cleaved RSS ends. Proc Natl Acad Sci USA 2001; 98:12926-12931. These three papers (Refs [27•-29•]) discuss the formation of the Rag1/2 synaptic complex on RSS prior to DNA cleavage.
30. Corneo B, Benmerah A, de Villartay JP. A short peptide at the C-terminus is responsible for the nuclear localization of RAG2. Eur J Immunol 2002; 32:2068-2073.
31. Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 and RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood 2001; 97:2772-2776.
32. Cavazzana-Calvo M, Le Deist F, de Saint Basile G, et al. Increased radiosensitivity of granulocyte macrophage colony-forming units and skin fibroblasts in human autosomal recessive severe combined immunodeficiency. J Clin Invest 1993; 91:1214-1218.
33. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Ann Rev Immunol 1991; 9:323-350.
34. Nicolas N, Moshous D, Papadopoulo D, et al. A human SCID condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 1998; 188:627-634.
35. Nicolas N, Finnie NJ, Cavazzana-Calvo M, et al. Lack of detectable defect in DNA double-strand break repair and DNA-dependent protein kinase activity in radiosensitive human severe combined immunodeficiency fibroblasts. Eur J Immunol 1996; 26:1118-1122.
36. Jones JF, Ritenbaugh CK, Spence MA, Hayward A. Severe combined immunodeficiency among the Navajo. I: Characterization of phenotypes, epidemiology, and population genetics. Hum Biol 1991; 63:669-682.
37. Moshous D, Li L, de Chasseval R, et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum Mol Genet 2000; 9:583-588.
38. Li L, Drayna D, Hu D, et al. The gene for severe combined immunodeficiency disease in Athabascan-speaking Native Americans is located on chromosome 10p. Am J Hum Genet 1998; 62:136-144.
39. Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking native Americans. J Immunol 2002; 168:6323-6329. This paper describes the Artemis non-sense mutation responsible for the RS-SCID phenotype in Athabascan speaking American Indians.
40. Wang Z, Fast W, Valentine AM, Benkovic SJ. Metallo-beta-lactamase: structure and mechanism. Curr Opin Chem Biol 1999; 3:614-622.
41. Aravind L. An evolutionary classification of the metallo-β-lactamase fold. In: Silico Biol. 1998. http://www.bioinfo.de/isb/1998/01/0008.
42. Daiyasu H, Osaka K, Ishino Y, Toh H. Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold. FEBS Lett 2001; 503:1-6.
43. Callebaut I, Moshous D, Mornon JP, De Villartay JP. Meta-β-lactamase fold within nucleic acids processing enzymes: the β-CASP family. Nucl Acids Res 2002; 30;3592-3601. In proteins involved in the metabolism of nucleic acids (DNA or RNA) that contain a metallo-β-lactamase fold, this domain is always associated to a new domain (β-CASP) which therefore defines a new family of protein of which Artemis is a member.
44. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998; 93:477-486.
45. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998; 93:467-476.
46. Chen HT, Bhandoola A, Difilippantonio MJ, et al. Response to RAG-mediated V(D)J cleavage by NBS1 and gamma-H2AX. Science 2000; 290:1962-1965.
47. Shockett PE, Schatz DG. DNA hairpin opening mediated by the RAG1 and RAG2 proteins. Mol Cell Biol 1999; 19:4159-4166.
48. Besmer E, Mansilla-Soto J, Cassard S, et al. Hairpin coding end opening is mediated by RAG1 and RAG2 proteins. Mol Cell 1998; 2:817-828.
49. Roth DB, Gellert M. New guardians of the genome. Nature 2000; 404:823-825.
50. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002; 108:781-794. Very elegant work which demonstrates the association and the phosphorylation of Artemis by DNA-PKcs. This complex then acquires an endonucleolytic activity capable of opening hairpins generated by Rag1/2, a hypothesis proposed in Ref. [5••].
51. Barnes DE, Stamp G, Rosewell I, et al. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 1998; 31:1395-1398.
52. Gao Y, Sun Y, Frank KM, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95:891-902.
53. Frank KM, Sekiguchi JM, Seidl KJ, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998; 396:173-177.
54. Li G, Nelsen C, Hendrickson EA. Ku86 is essential in human somatic cells. Proc Natl Acad Sci U S A 2002; 99:832-837. In contrast to the murine situation, a deficiency in Ku80 in humans may be nonviable according to this paper, which demonstrates cellular death in vitro caused by targeted inactivation of Ku80 in a human cell line.
55. Riballo E, Doherty AJ, Dai Y, et al. Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. J Biol Chem 2001; 276:31124-31132.
56. Riballo E, Critchlow SE, Teo SH, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999; 9:699-702.
57. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 2001; 8:1175-1185. Very elegant work that defines a new syndrome in humans associated with hypomorphic mutations in the DNA-ligase IV gene. These patients are immunodeficient and present developmental and growth delay resembling Nijmegen breakage syndrome. See also Refs [55,56] for a description of this new syndrome.
58. Verkaik NS, Esveldt-van Lange RE, van Heemst D, et al. Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol 2002; 32:701-709. This paper describes the development of a new DNA-repair assay that should help in identifying patients presenting defective NHEJ repair pathway.
59. Vanasse GJ, Concannon P, Willerford DM. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood 1999; 94:3997-4010.
60. Raghavan SC, Kirsch IR, Lieber MR. Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints. J Biol Chem 2001; 276:29126-29133.
61. Wyatt RT, Rudders RA, Zelenetz A, et al. BCL2 oncogene translocation is mediated by a chi-like consensus. J Exp Med 1992; 175:1575-1588.
62. Bernard O, Larsen CJ, Hampe A, et al. Molecular mechanisms of a t(8;14)(q24;q11) translocation juxtaposing c-myc and TcR-alpha genes in a T-cell leukaemia: involvement of a V alpha internal heptamer. Oncogene 1988; 2:195-200.
63. Cayuela JM, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 1997; 90:3720-3726.
64. Ferguson DO, Alt FW. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 2001; 20:5572-5579. Excellent review that discusses the development of lymphoid malignancies in animals, with targeted disruption of NHEJ factors.
65. Kinzler KW, Vogelstein B. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 1997; 386:761-763.
66. Zhu C, Mills KD, Ferguson DO, et al. Unrepaired DNA breaks in P53-deficient cells lead to oncogenic gene amplification subsequent to translocation. Cell 2002; 109:811-821. Very precise molecular analysis of the mechanisms that lead to the development of pro B cell lymphomas in XRCC4-/- and DNA-ligase IV-/- mice crossed onto a P53-/- background. Amplification of large genomic regions, associated with complex translocations that occur during abortive V(D)J recombination, is the basis for tumor progression in these mice.
67. Ferguson DO, Sekiguchi JM, Chang S, et al. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci U S A 2000; 97:6630-6633.
68. Difilippantonio MJ, Zhu J, Chen HT, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000; 404:510-514.
69. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 2000; 404:897-900.
70. Sharpless NE, Ferguson DO, O'Hagan RC, et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell 2001; 8:1187-1196. Defects in NHEJ factors not only cause lymphoid malignancies (see Refs [64••, 66••]), but also participate in the development of other types of cancer.
71. Roth DB, Craig NL. VDJ recombination: a transposase goes to work. Cell 1998; 94:411-414.
72. Agrawal A, Eastman QM, Schatz DG. Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. Nature 1998; 394:744-751.
73. Hiorn K, Melek M, Gellert M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell 1998; 94:463-470.
74. Melek M, Jones JM, O'Dea MH, et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci U S A 2002; 99:134-137. The results presented in this paper provide a new experimental argument in favor of the parallel between Rag1/2 and transposases.
75. Neiditch MB, Lee GS, Landree MA, Roth DB. RAG transposase can capture and commit to target DNA before or after donor cleavage. Mol Cell Biol 2001; 21:4302-4310.
76. Neiditch MB, Lee GS, Huye LE, et al. The v(d)j recombinase efficiently cleaves and transposes signal joints. Mol Cell 2002; 9:871-878. Although it was thought that signal-joints represented a safe way to avoid potentially reactive signal ends to mediate transposition in vivo, this paper demonstrates that signal-joints can be re-cut by the Rag1/2 complex.
77. Lee GS, Neiditch MB, Sinden RR, Roth DB. Targeted transposition by the V(D)J recombinase. Mol Cell Biol 2002; 22:2068-2077.
78. Bassing CH, Chua KF, Sekiguchi J, et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 2002; 28:8173-8178. This paper demonstrates that H2AX is not required for V(D)J recombination to occur.
79. Ooi SL, Shoemaker DD, Boeke JD. A DNA microarray-based genetic screen for nonhomologous end-joining mutants in Saccharomyces cerevisiae. Science 2001; 294:2552-2556.
80. Valencia M, Bentele M, Vaze MB, et al. NEJ1 controls non-homologous end joining in Saccharomyces cerevisiae. Nature 2001; 414:666-669.
81. Kegel A, Sjostrand JO, Astrom SU. Nej1p, a cell type-specific regulator of nonhomologous end joining in yeast. Curr Biol 2001; 11:1611-1617.
82. Frank-Vaillant M, Marcand S. NHEJ regulation by mating type is exercised through a novel protein, Lif2p, essential to the ligase IV pathway. Genes Dev 2001; 15:3005-3012.
83. Mahajan KN, Nick McElhinny SA, Mitchell BS, Ramsden DA. Association of DNA polymerase micro (pol micro) with Ku and ligase IV: role for pol micro in end-joining double-strand break repair. Mol Cell Biol 2002; 22:5194-5202. See annotation to Ref. [84•].
84. Chappell C, Hanakahi LA, Karimi-Busheri F, et al. Involvement of human polynucleotide kinase in double-strand break repair by non-homologous end joining. EMBO J 2002; 21:2827-2832. These two papers (Refs [83•,84•]) indirectly suggest that Pol μ and polynucleotide kinase could represent a new actor of the V(D)J recombination based on their implication in the NHEJ pathway.